PharmaCielo Ltd.

As of June 30, 2026, PharmaCielo Ltd. carries a market capitalization of 13.73M, placing it among publicly traded companies globally. Its enterprise value stands at 31.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PharmaCielo Ltd.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, PharmaCielo Ltd. has 211.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.53, and the price-to-book ratio stands at -1.28.

As of June 30, 2026, PharmaCielo Ltd. trades at an EV/EBITDA multiple of 379.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 31.87M versus a market cap of 13.73M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PharmaCielo Ltd. maintains a current ratio of 0.14, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -170.28, indicating conservative leverage, while an interest coverage ratio of 0.03 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -21.33, reflecting losses generated across the asset base. The company generates approximately 13,446.90 in revenue per employee across its workforce of 268.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.16 indicates how many times PharmaCielo Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, PharmaCielo Ltd.'s stock has gained approximately 11.11% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.07.

Over the twelve months ended June 30, 2026, PharmaCielo Ltd. generated 3.60M in revenue and converted that into -3.71M in net income, yielding earnings per share of -0.02. EBITDA reached 83,920.00, while operating income came in at -3.16M.

As of June 30, 2026, PharmaCielo Ltd. holds 77,498.00 in cash and equivalents against 18.21M in total debt, resulting in a net debt position of 18.14M. Total book value stands at -10.70M, with working capital of -20.26M providing operational flexibility.

PharmaCielo Ltd. produced -6.96M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PharmaCielo Ltd. posted a gross margin of 36.19, reflecting its pricing power and cost economics. The operating margin of -87.56 and net profit margin of -103.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -54.66: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 22.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PharmaCielo Ltd. shareholders.

PharmaCielo Ltd.'s most recent stock split took place on January 18, 2019 with a 597:50 split ratio.

As of June 30, 2026, PharmaCielo Ltd. has an Altman Z-Score of -25.72, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.